Real-world evaluation of interstitial lung disease/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan

医学 入射(几何) 上市后监督 内科学 间质性肺病 肺 曲妥珠单抗 肿瘤科 安全概况 胃肠病学 临床试验 外科
作者
Hisato Kawakami,K. Uchino,Wataru Hashimoto,Kei Muro
出处
期刊:ESMO open [Elsevier BV]
卷期号:10 (12): 105914-105914 被引量:10
标识
DOI:10.1016/j.esmoop.2025.105914
摘要

BACKGROUND: Interstitial lung disease (ILD)/pneumonitis is an important identified risk associated with trastuzumab deruxtecan (T-DXd) treatment, but there are few reports of T-DXd-related ILD in a real-world setting. MATERIALS AND METHODS: This observational, multicenter, all-patient postmarketing surveillance study in patients with gastric cancer treated with T-DXd in a real-world setting in Japan investigated the incidence and characteristics of drug-related ILD and factors of interest associated with its incidence. All patients who initiated T-DXd treatment for human epidermal growth factor receptor 2 (HER2)-positive unresectable advanced or recurrent gastric cancer between September 2020 and December 2021 were enrolled and observed until T-DXd therapy termination or completion of 12 months of treatment. All potential ILD cases occurring during or after T-DXd treatment were reported by the investigators and evaluated. The primary outcome was adjudicated drug-related ILD. RESULTS: In the safety analysis set (n = 1070), 77.4% were males and the median age was 70 years (range 23-100 years). The median treatment duration of T-DXd was 3.9 months (range 0.7-12.0 months). The incidence of any grade, grade ≥3, and grade 5 adjudicated drug-related ILD was 9.6%, 2.8%, and 1.2%, respectively. The median time from first T-DXd treatment to the first onset of adjudicated drug-related ILD episode was 2.9 months (range 0.3-11.5 months). The most common imaging pattern at the onset of adjudicated drug-related ILD was organizing pneumonia (62.1%), followed by hypersensitivity pneumonitis (20.4%) and diffuse alveolar damage (7.8%). Age (≥75 years), medical history and/or comorbidity of ILD, radiation pneumonitis, and chronic obstructive pulmonary disease (COPD) or emphysema were identified as factors of interest for ILD incidence. CONCLUSION: The incidence of ILD with T-DXd in the real-world setting was similar to that observed in clinical trials, indicating no new ILD-related safety signals. Further investigation of the identified factors may offer insights into ILD incidence in high-risk populations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wangbq完成签到 ,获得积分10
刚刚
胖胖完成签到,获得积分10
刚刚
2秒前
欣喜香菇发布了新的文献求助10
2秒前
忧虑的牛排完成签到,获得积分10
3秒前
机灵奇迹完成签到,获得积分10
3秒前
别摆烂了完成签到,获得积分10
4秒前
陆lu完成签到,获得积分10
4秒前
5秒前
5秒前
大个的应助被神勇的曼文采纳,获得10
6秒前
6秒前
7秒前
打打的应助被司徒宝采纳,获得10
7秒前
uri发布了新的文献求助10
7秒前
369ninja的应助被青丝采纳,获得10
8秒前
所所的应助被wang采纳,获得10
8秒前
8秒前
李健的应助被AA采纳,获得10
8秒前
daomaihu发布了新的文献求助100
10秒前
哈哈哈完成签到,获得积分10
10秒前
吃猫的鱼发布了新的文献求助10
12秒前
12秒前
12秒前
荣离枯发布了新的文献求助10
12秒前
YU发布了新的文献求助10
12秒前
12秒前
惠1完成签到,获得积分10
13秒前
power发布了新的文献求助10
13秒前
传奇3的应助被wang采纳,获得10
13秒前
小薇薇完成签到,获得积分20
14秒前
14秒前
14秒前
王士豪发布了新的文献求助10
15秒前
www完成签到,获得积分10
15秒前
一路顺风完成签到 ,获得积分10
16秒前
高高靳发布了新的文献求助10
17秒前
gemma发布了新的文献求助30
17秒前
无心的谷槐完成签到,获得积分10
17秒前
万能图书馆的应助被大壮采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175267
求助须知:如何正确求助?哪些是违规求助? 9567035
关于积分的说明 21789830
捐赠科研通 7769741
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477241